Synairgen (LON:SNG) Trading 22% Higher – Still a Buy?

Synairgen plc (LON:SNG) shares shot up 22% during mid-day trading on Wednesday . The company traded as high as GBX 2.71 ($0.03) and last traded at GBX 2.68 ($0.03). 1,771,337 shares changed hands during mid-day trading, an increase of 25% from the average session volume of 1,421,729 shares. The stock had previously closed at GBX 2.20 ($0.03).

Synairgen Price Performance

The stock has a market capitalization of £3.69 million, a P/E ratio of -61.03 and a beta of -2.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.35 and a current ratio of 6.77. The firm has a 50-day moving average price of GBX 3.60 and a 200 day moving average price of GBX 3.96.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).